Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Global Trends of Treatment for NAFLD from 2012 to 2021: A Bibliometric and Mapping Analysis

Author(s): Yuling Song, Boru Chen, Lu Jiang, Fangkun Zhao and Xiuqin Feng*

Volume 24, Issue 5, 2024

Published on: 06 October, 2023

Page: [573 - 584] Pages: 12

DOI: 10.2174/0118715303230418230925060312

Price: $65

Abstract

Aim: The present study aimed to map publication trends and explore research hotspots of treatment for NAFLD study by bibliometric analysis.

Background: Nonalcoholic fatty liver disease (NAFLD) is a multi-system metabolic disorder involving the liver. Thousands of papers have been published on the treatment of NAFLD, but no comprehensive statistical and intuitive analysis has been made. The present study aimed to map publication trends and explore research hotspots of treatment for NAFLD study by bibliometric analysis.

Objective: (1) The pathogenesis of NAFLD and the possible treatment mechanism; (2) prevalence, risk factors, and traditional therapies for NAFLD; (3) frontier therapies for NAFLD.

Method; This paper conducted a bibliometric analysis based on the Web of Science Core Collection (WoSCC). The knowledge map was constructed by VOS viewer v.1.6.10 to visualize the annual publication number, the distribution of countries, international collaborations, author productivity, source journals, cited references, and keywords in this field.

Results: From 2012 to 2021, 2,437 peer-reviewed publications on the treatment of NAFLD were retrieved. China contributed the most publications, while the United States received the most citations. Journal of Hepatology was the most prolific journal in this field. Prof. Rohit Loomba.

Conclusion: Our study provides a comprehensive and objective analysis of NAFLD treatment that allows researchers to quickly locate research hotspots in a large number of relevant literatures. Meanwhile, it may also provide valuable information for researchers looking for potential partners and institutions.

« Previous Next »
[1]
Blond, E.; Disse, E.; Cuerq, C.; Drai, J.; Valette, P.J.; Laville, M.; Thivolet, C.; Simon, C.; Caussy, C. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: Do they lead to over-referral? Diabetologia, 2017, 60(7), 1218-1222.
[http://dx.doi.org/10.1007/s00125-017-4264-9] [PMID: 28352941]
[2]
Oseini, AM; Sanyal, AJ Therapies in non-alcoholic steatohepatitis. Liver Int., 2017, 37(Suppl 1), 97-103.
[3]
Lomonaco, R.; Chen, J.; Cusi, K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther. Adv. Endocrinol. Metab., 2011, 2(5), 211-225.
[http://dx.doi.org/10.1177/2042018811419157] [PMID: 23148186]
[4]
Zou, X.; Yue, W.L.; Vu, H.L. Visualization and analysis of mapping knowledge domain of road safety studies. Accid. Anal. Prev., 2018, 118, 131-145.
[http://dx.doi.org/10.1016/j.aap.2018.06.010] [PMID: 29958121]
[5]
Song, Y.; Zhao, F. Bibliometric analysis of metabolic surgery for type 2 diabetes: Current status and future prospects. Updates Surg., 2022, 74(2), 697-707.
[http://dx.doi.org/10.1007/s13304-021-01201-5] [PMID: 35094308]
[6]
Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol., 2015, 62(1)(Suppl.), S47-S64.
[http://dx.doi.org/10.1016/j.jhep.2014.12.012] [PMID: 25920090]
[7]
Day, C.P.; James, O.F.W. Steatohepatitis: A tale of two “hits”? Gastroenterology, 1998, 114(4), 842-845.
[http://dx.doi.org/10.1016/S0016-5085(98)70599-2] [PMID: 9547102]
[8]
Baeck, C.; Wehr, A.; Karlmark, K.R.; Heymann, F.; Vucur, M.; Gassler, N.; Huss, S.; Klussmann, S.; Eulberg, D.; Luedde, T.; Trautwein, C.; Tacke, F. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut, 2012, 61(3), 416-426.
[http://dx.doi.org/10.1136/gutjnl-2011-300304] [PMID: 21813474]
[9]
Armstrong, M.J.; Gaunt, P.; Aithal, G.P.; Barton, D.; Hull, D.; Parker, R.; Hazlehurst, J.M.; Guo, K.; Abouda, G.; Aldersley, M.A.; Stocken, D.; Gough, S.C.; Tomlinson, J.W.; Brown, R.M.; Hübscher, S.G.; Newsome, P.N. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, 2016, 387(10019), 679-690.
[http://dx.doi.org/10.1016/S0140-6736(15)00803-X] [PMID: 26608256]
[10]
Ranjbar, G.; Mikhailidis, D.P.; Sahebkar, A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism, 2019, 101, 154001.
[http://dx.doi.org/10.1016/j.metabol.2019.154001] [PMID: 31672448]
[11]
Perumpail, B.; Li, A.; John, N.; Sallam, S.; Shah, N.; Kwong, W.; Cholankeril, G.; Kim, D.; Ahmed, A. The therapeutic implications of the gut microbiome and probiotics in patients with NAFLD. Diseases, 2019, 7(1), 27.
[http://dx.doi.org/10.3390/diseases7010027] [PMID: 30823570]
[12]
Opitz, C.A.; Somarribas Patterson, L.F.; Mohapatra, S.R.; Dewi, D.L.; Sadik, A.; Platten, M.; Trump, S. The therapeutic potential of targeting tryptophan catabolism in cancer. Br. J. Cancer, 2020, 122(1), 30-44.
[http://dx.doi.org/10.1038/s41416-019-0664-6] [PMID: 31819194]
[13]
Fink, D.; Dobbelstein, E.; Barbian, A.; Lohaus, G. Ratio of sugar concentrations in the phloem sap and the cytosol of mesophyll cells in different tree species as an indicator of the phloem loading mechanism. Planta, 2018, 248(3), 661-673.
[http://dx.doi.org/10.1007/s00425-018-2933-7] [PMID: 29882156]
[14]
Kleiner, D.E.; Brunt, E.M.; Van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.C.; Torbenson, M.S.; Unalp-Arida, A.; Yeh, M.; McCullough, A.J.; Sanyal, A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41(6), 1313-1321.
[http://dx.doi.org/10.1002/hep.20701] [PMID: 15915461]
[15]
Jiang, B.; Chen, Y.; Zhou, K.; Zheng, Y.; Chen, Y.; Li, Q.; Zhu, C.; Xia, F.; Gu, T.; Guo, Y.; Lu, Y. comparison of abdominal obesity and fatty liver and their association with insulin resistance and metabolic syndrome in chinese adults. Obesity (Silver Spring), 2019, 27(5), oby.22432.
[http://dx.doi.org/10.1002/oby.22432] [PMID: 30942551]
[16]
Brunt, E.M.; Wong, V.W.S.; Nobili, V.; Day, C.P.; Sookoian, S.; Maher, J.J.; Bugianesi, E.; Sirlin, C.B.; Neuschwander-Tetri, B.A.; Rinella, M.E. Nonalcoholic fatty liver disease. Nat. Rev. Dis. Primers, 2015, 1(1), 15080.
[http://dx.doi.org/10.1038/nrdp.2015.80] [PMID: 27188459]
[17]
Hu, M.; Phan, F.; Bourron, O.; Ferré, P.; Foufelle, F. Steatosis and NASH in type 2 diabetes. Biochimie, 2017, 143, 37-41.
[http://dx.doi.org/10.1016/j.biochi.2017.10.019] [PMID: 29097281]
[18]
Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65(8), 1038-1048.
[http://dx.doi.org/10.1016/j.metabol.2015.12.012] [PMID: 26823198]
[19]
Li, F.; Sun, G.; Wang, Z.; Wu, W.; Guo, H.; Peng, L.; Wu, L.; Guo, X.; Yang, Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci. China Life Sci., 2018, 61(7), 770-778.
[http://dx.doi.org/10.1007/s11427-017-9303-9] [PMID: 29948900]
[20]
Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010, 52(5), 1836-1846.
[http://dx.doi.org/10.1002/hep.24001] [PMID: 21038418]
[21]
Dasgupta, D.; Nakao, Y.; Mauer, A.S.; Thompson, J.M.; Sehrawat, T.S.; Liao, C.Y.; Krishnan, A.; Lucien, F.; Guo, Q.; Liu, M.; Xue, F.; Fukushima, M.; Katsumi, T.; Bansal, A.; Pandey, M.K.; Maiers, J.L.; DeGrado, T.; Ibrahim, S.H.; Revzin, A.; Pavelko, K.D.; Barry, M.A.; Kaufman, R.J.; Malhi, H. IRE1A stimulates hepatocyte-derived extracellular vesicles that promote inflammation in mice with steatohepatitis. Gastroenterology, 2020, 159(4), 1487-1503.e17.
[http://dx.doi.org/10.1053/j.gastro.2020.06.031] [PMID: 32574624]
[22]
Lee, Y.A.; Friedman, S.L. Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies. J. Intern. Med., 2022, 291(1), 11-31.
[http://dx.doi.org/10.1111/joim.13380] [PMID: 34564899]
[23]
Loomba, R.; Friedman, S.L.; Shulman, G.I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184(10), 2537-2564.
[http://dx.doi.org/10.1016/j.cell.2021.04.015] [PMID: 33989548]
[24]
Campos-Murguía, A.; Ruiz-Margáin, A.; González-Regueiro, J.A.; Macías-Rodríguez, R.U. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J. Gastroenterol., 2020, 26(39), 5919-5943.
[http://dx.doi.org/10.3748/wjg.v26.i39.5919] [PMID: 33132645]
[25]
European Association for the Study of the Liver (EASL). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 2016, 64(6), 1388-1402.
[http://dx.doi.org/10.1016/j.jhep.2015.11.004] [PMID: 27062661]
[26]
Feng, G.; Li, X.P.; Niu, C.Y.; Liu, M.L.; Yan, Q.; Fan, L.P.; Li, Y.; Zhang, K.L.; Gao, J.; Qian, M.R.; He, N.; Mi, M. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gene, 2020, 742, 144549.
[http://dx.doi.org/10.1016/j.gene.2020.144549] [PMID: 32184169]
[27]
Abenavoli, L.; Boccuto, L.; Federico, A.; Dallio, M.; Loguercio, C.; Di Renzo, L.; De Lorenzo, A. diet and non-alcoholic fatty liver disease: the mediterranean way. Int. J. Environ. Res. Public Health, 2019, 16(17), 3011.
[http://dx.doi.org/10.3390/ijerph16173011] [PMID: 31438482]
[28]
Fougerat, A.; Montagner, A.; Loiseau, N.; Guillou, H.; Wahli, W. Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease. Cells, 2020, 9(7), 1638.
[http://dx.doi.org/10.3390/cells9071638] [PMID: 32650421]
[29]
Musso, G.; Cassader, M.; Paschetta, E.; Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis. JAMA Intern. Med., 2017, 177(5), 633-640.
[http://dx.doi.org/10.1001/jamainternmed.2016.9607] [PMID: 28241279]
[30]
Leoni, S.; Tovoli, F.; Napoli, L.; Serio, I.; Ferri, S.; Bolondi, L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J. Gastroenterol., 2018, 24(30), 3361-3373.
[http://dx.doi.org/10.3748/wjg.v24.i30.3361] [PMID: 30122876]
[31]
Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A.; Van Natta, M.; Clark, J.; Brunt, E.M.; Kleiner, D.E.; Hoofnagle, J.H.; Robuck, P.R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 2010, 362(18), 1675-1685.
[http://dx.doi.org/10.1056/NEJMoa0907929] [PMID: 20427778]
[32]
Mantovani, A.; Byrne, C.D.; Scorletti, E.; Mantzoros, C.S.; Targher, G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab., 2020, 46(6), 427-441.
[http://dx.doi.org/10.1016/j.diabet.2019.12.007] [PMID: 31923578]
[33]
Neuschwander-Tetri, B.A.; Loomba, R.; Sanyal, A.J.; Lavine, J.E.; Van Natta, M.L.; Abdelmalek, M.F.; Chalasani, N.; Dasarathy, S.; Diehl, A.M.; Hameed, B.; Kowdley, K.V.; McCullough, A.; Terrault, N.; Clark, J.M.; Tonascia, J.; Brunt, E.M.; Kleiner, D.E.; Doo, E. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet, 2015, 385(9972), 956-965.
[http://dx.doi.org/10.1016/S0140-6736(14)61933-4] [PMID: 25468160]
[34]
Neuschwander-Tetri, B.A. Therapeutic landscape for NAFLD in 2020. Gastroenterology, 2020, 158(7), 1984-1998.e3.
[http://dx.doi.org/10.1053/j.gastro.2020.01.051] [PMID: 32061596]
[35]
Boursier, J.; Mueller, O.; Barret, M.; Machado, M.; Fizanne, L.; Araujo-Perez, F.; Guy, C.D.; Seed, P.C.; Rawls, J.F.; David, L.A.; Hunault, G.; Oberti, F.; Calès, P.; Diehl, A.M. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology, 2016, 63(3), 764-775.
[http://dx.doi.org/10.1002/hep.28356] [PMID: 26600078]
[36]
Brandl, K.; Schnabl, B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol., 2017, 33(3), 128-133.
[http://dx.doi.org/10.1097/MOG.0000000000000349] [PMID: 28257306]
[37]
Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G.; Galvano, F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci., 2012, 57(2), 545-553.
[http://dx.doi.org/10.1007/s10620-011-1887-4] [PMID: 21901256]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy